HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

December 29th 2018

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.

Trastuzumab ADCC May Affect Outcomes in HER2+ Breast Cancer

December 28th 2018

Patients with HER2-positive early or locally advanced breast cancer who were exposed to reference trastuzumab lots with a marked downward shift in antibody-dependent cell-mediated cytotoxicity (ADCC) had worse outcomes than those not exposed to at least 1 shifted ADCC lot or those treated with its biosimilar.

Dr. Tripathy Discusses Pertuzumab in HER2+ Breast Cancer

December 21st 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.

Neratinib Improves PFS in HER2+ Metastatic Breast Cancer

December 19th 2018

Neratinib led to a statistically significant improvement in centrally confirmed progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy.

De-Escalation Possible in Curative Setting for HER2+ Breast Cancer

December 18th 2018

Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.

T-DM1 May Provide Less-Toxic Option in Older HER2+ Breast Cancer Population

December 14th 2018

Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.

Dr. Rimawi on Treatment of Metastatic HER2+ Breast Cancer

December 13th 2018

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the current treatment paradigm for patients with metastatic HER2-positive breast cancer.

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer

December 11th 2018

Paradigm Evolving in HER2+ Breast Cancer With CNS Mets

December 11th 2018

Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.

ACE Inhibitor, Beta Blocker Lower Trastuzumab Cardiotoxicity Risk in HER2+ Breast Cancer

December 10th 2018

In patients with early-stage HER2-positive breast cancer who are being treated with adjuvant trastuzumab and anthracyclines, cardiotoxicity-free survival is longer when they receive prophylactic simultaneous lisinopril or carvedilol.

Palbociclib Combo Active in HER2+ Breast Cancer

December 7th 2018

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer

December 6th 2018

Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.

Dr. Pincus on Classifying HER2+ Tumors in Breast Cancer

December 4th 2018

Jenny Pincus, MD, assistant professor of pathology, Northwestern University, Feinberg School of Medicine, discusses the classification of HER2-positive tumors in patients with breast cancer.

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

November 29th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Dr. O'Sullivan Discusses the Future of HER2+ Breast Cancer Treatment

November 27th 2018

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the future for HER2-positive breast cancer treatment.

Dr. O'Regan on Impact of Targeted Agents in HER2+ Breast Cancer

November 22nd 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.

Adjuvant Options Expand in HER2+ Breast Cancer, But Questions Remain

November 16th 2018

Vik Gorantla, MD, discusses ongoing developments in the adjuvant setting for patients with HER2-positive breast cancer.

Addressing De-Escalation of Treatment in HER2+ Breast Cancer

November 15th 2018

Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer.

Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats

November 14th 2018

Mohammed Rahman, MD, discusses ongoing efforts to optimize the use of neratinib in patients with HER2-positive breast cancer.

Dr. Gorantla on the Impact of the APHINITY Trial in HER2+ Breast Cancer

November 14th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, discusses the impact of the APHINITY trial on the treatment of patients with HER2-positive breast cancer.